Incidence and Survival of Patients with Small Intestinal Neuroendocrine Tumours in a Danish NET Center

Table 4

Treatment.

	Group 1	Group 2	𝑃 value
Primary surgery:	80.8% (42/52)	75.2% (82/109)	0.549
(i) macroscopically radical	19.0% (8/42)	56.1% (46/82)	0.000
(ii) not macroscopically radical	81.0% (34/42)	43.9% (36/82)
Interferon	65.4% (34/52)	42.2% (46/109)	0.007
Somatostatin analogues	73.1% (38/52)	66.1% (72/109)	0.470
Radionuclide treatment	9.6% (5/52)	13.8% (15/109)	0.610
Radiofrequency ablation (RFA)	1.9% (1/52)	15.6% (17/109)	0.008
Systemic chemotherapy	5.8% (3/52)	4.6% (5/109)	0.710
Temozolomide	1.9% (1/52)	1.8% (2/109)	1.000
Embolisation	0.0% (0/52)	8.3% (9/109)	0.030
New surgery:
(i) none	100% (52/52)	89.9% (98/109)	0.000
(ii) small bowel resection	0.0% (0/52)	3.7% (4/109)
(iii) lymph node resection	0.0% (0/52)	0.9% (1/109)
(iv) liver resection	0.0% (0/52)	4.6% (5/109)
(v) bone resection	0.0% (0/52)	0.9% (1/109)
New surgery in total	0.0%	10.1%